Exact Sciences Corporation (FRA:EXK)

Market Cap	16.76B +69.1%
Revenue (ttm)	2.77B +17.7%
Net Income	-177.11M
EPS	-0.94
Shares Out	n/a
PE Ratio	n/a
Forward PE	81.22
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	0
Open	87.55
Previous Close	87.25
Day's Range	87.55 - 87.55
52-Week Range	33.80 - 88.16
Beta	n/a
RSI	59.57
Earnings Date	Feb 17, 2026

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients...

• Industry: Commercial Physical and Biological Research
• Founded: 1995
• Employees: 7,150
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: EXK

Financial Performance

In 2025, Exact Sciences's revenue was $3.25 billion, an increase of 17.69% compared to the previous year's $2.76 billion. Losses were -$207.95 million, -79.79% less than in 2024.

Financial numbers in USD